RxDoctor Payments Data

Mark Stokes, MD

Ophthalmology · Florence, SCNPI 1013910595

Payments from drug & device makers

$620in general payments, 2019–2025

Across 28 payments — averaging $22.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Surgical Vision, Inc.$187
  • ANI Pharmaceuticals, Inc.$100
  • Alcon$66
  • Kala Pharmaceuticals, Inc.$43
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$42
  • Novartis$33
  • plus $149 from 7 others

What the payments were for

  • Food & beverage$620100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$620 in reported general payments places this provider in the 20th percentile of 293 ophthalmology providers in South Carolina.

See all ophthalmology providers in South Carolina

Medicare billing

Part B allowed, 2024
$329,498
Medicare patients
1,257
Services billed
4,285

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine19$30,521
LumiganBimatoprost69$26,374
BesivanceBesifloxacin Hcl76$16,498
XiidraLifitegrast23$16,015
CombiganBrimonidine Tartrate/Timolol41$11,798
ProlensaBromfenac Sodium31$10,599
Cyclosporine13$8,519
Brimonidine Tartrate82$6,157
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol50$5,994
Difluprednate54$5,679
Prednisolone Acetate112$5,264
Bromfenac Sodium25$4,755
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha324$3,662
Latanoprost366$3,375
Timolol Maleate66$2,499

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$30$68,693129 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCBesivance, Prolensa$42$27,097107 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 293 ophthalmology providers in South Carolina.

Other ophthalmology in Florence

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →